Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis
{{output}}
Background: In 2024, Alzheimer's disease affected approximately 6.9 million Americans aged 65 and older. Current therapies include acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor inhibitors, and monoclonal antibod... ...
